Jaguar Health Inc. (JAGX)
| Bid | 3.32 |
| Market Cap | 3.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 505 |
| PE Ratio (ttm) | 0.01 |
| Forward PE | -0.46 |
| Analyst | n/a |
| Ask | 5.79 |
| Volume | 40,833 |
| Avg. Volume (20D) | 23,851 |
| Open | 4.67 |
| Previous Close | 4.76 |
| Day's Range | 4.40 - 4.70 |
| 52-Week Range | 4.40 - 540.00 |
| Beta | 0.81 |
About JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer fo...
Earnings Surprise
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago · accessnewswire.com
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget StudyThe statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste...
2 weeks ago · accessnewswire.com
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of StockholdersJaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis...
